London, UK-based Rexgenero has secured with partners £1.4 million in funding for a £1.8 million project from the UK’s innovation agency Innovate UK, for an industrial research project on the commercial manufacture of its product REX-001. More: Rexgenero wins £1.4m
read moreAstellas’ experimental acute myeloid leukaemia drug gilteritinib has been awarded orphan drug designation by the European Commission. More: Astellas bags orphan drug status for AML drug Source: News
read moreCost regulators for NHS-funded therapies in England and Wales have issued updated guidelines for the treatment of wet AMD, which continue to back use of both Bayer’s Eylea and Novartis’ Lucentis, but the GMC says doctors should not fear prescribing
read moreThe European Commission has extended conditional marketing authorisation for Takeda’s Adcetris to include the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL) following one prior systemic therapy. More: EC OKs Adcetris for CD30-positive cutaneous T-cell lymphoma Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals